Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PTPRF | P10586 | 13/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 13/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 13/20 | 0.49 |
| ▸ | ECE1 | P42892 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302058 | 0.85 | PDE4B (0.47) | PDE4APDE4BPDE4CPDE4DPTPRF | |
| SCHEMBL12108196 | 0.83 | PTPRF (0.42) | PTPRFPTPN2PTPN1ALDH1A1 | |
| SCHEMBL1300889 | 0.82 | PDE4B (0.57) | PDE4APDE4BPDE4CPDE4DPTPRF | |
| SCHEMBL1301794 | 0.75 | PDE4B (0.59) | PDE4APDE4BPDE4CPDE4DPTPRF | |
| SCHEMBL1302486 | 0.73 | PDE4B (0.59) | PDE4APDE4BPDE4CPDE4DPTPRF | |
| SCHEMBL1300847 | 0.71 | PDE4B (0.53) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| Tetomilast SCHEMBL29369138 | 0.70 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DECE1 | |
| Tetomilast SCHEMBL436663 | 0.70 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL12108198 | 0.70 | PTPRF (0.38) | PDE4BPTPRFPTPN2PTPN1 | |
| SCHEMBL5026716 | 0.69 | TTR (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | claimed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | claimed |
| EP-2379538-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-26 | — | — | EP | claimed |
| WO-2010084402-A2 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | claimed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.